Israel’s D-Pharm has expanded its commercial agreement with China’s Wanbang Biopharmaceuticals Ltd. for D Pharm’s leading product, DP-b99 for the treatment of ischemic stroke.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000714276&fid=1725
Expanding stroke treatment in China
This entry was posted in Economy & Business. Bookmark the permalink.